Heterogeneous p53 mutations in a Burkitt lymphoma from an AIDS patient with monoclonal c-myc and VDJ rearrangements. 1997

P Campomenosi, and G Fronza, and L Ottaggio, and S Roncella, and A Inga, and M Bogliolo, and P Monti, and P Assereto, and F Moro, and G Cutrona, and S Bozzo, and N Chiorazzi, and A Abbondandolo, and M Ferrarini
CSTA-Mutagenesis Laboratory, National Institute for Cancer Research (IST), Genoa, Italy.

This study investigates the timing of p53 mutations detected in the malignant cells of a Burkitt's lymphoma cell line (BRG-P) with respect to other maturation or transforming events. The BRG-P cell line, derived from an AIDS patient, was of special value since it displayed subclones that had undergone an isotype switch from IgM to IgA1 (BRG-M and BRG-A cells). BRG-M and BRG-A cells were characterized by the same monoclonal c-myc and VDJ rearrangements and by the expression of Ig receptors with specificity for a 45 kDa protein of human breast cells. Analysis of p53 mutations in the different BRG subclones showed that 1) BRG-M cells displayed 2 different p53 mutations in trans; since the original BL cells also showed the same mutations, this finding indicated that both occurred in vivo; 2) one of the p53 alleles of BRG-A cells was lost, while the other showed a mutation different from those seen in BRG-M cells; and 3) all 3 mutations observed in BRG-M or BRG-A cells resulted in the functional inactivation of the transcriptional activation function of p53. Together, our data demonstrate that p53 mutations were relatively late events during lymphomagenesis. Moreover, in view of the role of p53 in cell apoptosis, it is conceivable that BRG cells were subjected to a strong selective pressure that favored p53 inactivation. Such inactivation was possibly required to counterbalance other potentially apoptotic events, including the presence of a deregulated c-myc oncogene and signals delivered by the host environment in situ.

UI MeSH Term Description Entries
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D002872 Chromosome Deletion Actual loss of portion of a chromosome. Monosomy, Partial,Partial Monosomy,Deletion, Chromosome,Deletions, Chromosome,Monosomies, Partial,Partial Monosomies
D005260 Female Females
D005803 Genes, Immunoglobulin Genes encoding the different subunits of the IMMUNOGLOBULINS, for example the IMMUNOGLOBULIN LIGHT CHAIN GENES and the IMMUNOGLOBULIN HEAVY CHAIN GENES. The heavy and light immunoglobulin genes are present as gene segments in the germline cells. The completed genes are created when the segments are shuffled and assembled (B-LYMPHOCYTE GENE REARRANGEMENT) during B-LYMPHOCYTE maturation. The gene segments of the human light and heavy chain germline genes are symbolized V (variable), J (joining) and C (constant). The heavy chain germline genes have an additional segment D (diversity). Genes, Ig,Immunoglobulin Genes,Gene, Ig,Gene, Immunoglobulin,Ig Gene,Ig Genes,Immunoglobulin Gene
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015321 Gene Rearrangement The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development. DNA Rearrangement,DNA Rearrangements,Gene Rearrangements,Rearrangement, DNA,Rearrangement, Gene,Rearrangements, DNA,Rearrangements, Gene
D016158 Genes, p53 Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53. Genes, TP53,TP53 Genes,p53 Genes,Gene, TP53,Gene, p53,TP53 Gene,p53 Gene

Related Publications

P Campomenosi, and G Fronza, and L Ottaggio, and S Roncella, and A Inga, and M Bogliolo, and P Monti, and P Assereto, and F Moro, and G Cutrona, and S Bozzo, and N Chiorazzi, and A Abbondandolo, and M Ferrarini
September 1995, Leukemia & lymphoma,
P Campomenosi, and G Fronza, and L Ottaggio, and S Roncella, and A Inga, and M Bogliolo, and P Monti, and P Assereto, and F Moro, and G Cutrona, and S Bozzo, and N Chiorazzi, and A Abbondandolo, and M Ferrarini
December 2008, Leukemia research,
P Campomenosi, and G Fronza, and L Ottaggio, and S Roncella, and A Inga, and M Bogliolo, and P Monti, and P Assereto, and F Moro, and G Cutrona, and S Bozzo, and N Chiorazzi, and A Abbondandolo, and M Ferrarini
February 2022, BMJ case reports,
P Campomenosi, and G Fronza, and L Ottaggio, and S Roncella, and A Inga, and M Bogliolo, and P Monti, and P Assereto, and F Moro, and G Cutrona, and S Bozzo, and N Chiorazzi, and A Abbondandolo, and M Ferrarini
November 1987, Science (New York, N.Y.),
P Campomenosi, and G Fronza, and L Ottaggio, and S Roncella, and A Inga, and M Bogliolo, and P Monti, and P Assereto, and F Moro, and G Cutrona, and S Bozzo, and N Chiorazzi, and A Abbondandolo, and M Ferrarini
February 1999, Cancer,
P Campomenosi, and G Fronza, and L Ottaggio, and S Roncella, and A Inga, and M Bogliolo, and P Monti, and P Assereto, and F Moro, and G Cutrona, and S Bozzo, and N Chiorazzi, and A Abbondandolo, and M Ferrarini
August 2013, World journal of gastroenterology,
P Campomenosi, and G Fronza, and L Ottaggio, and S Roncella, and A Inga, and M Bogliolo, and P Monti, and P Assereto, and F Moro, and G Cutrona, and S Bozzo, and N Chiorazzi, and A Abbondandolo, and M Ferrarini
September 2008, Human pathology,
P Campomenosi, and G Fronza, and L Ottaggio, and S Roncella, and A Inga, and M Bogliolo, and P Monti, and P Assereto, and F Moro, and G Cutrona, and S Bozzo, and N Chiorazzi, and A Abbondandolo, and M Ferrarini
February 2024, Cureus,
P Campomenosi, and G Fronza, and L Ottaggio, and S Roncella, and A Inga, and M Bogliolo, and P Monti, and P Assereto, and F Moro, and G Cutrona, and S Bozzo, and N Chiorazzi, and A Abbondandolo, and M Ferrarini
January 1996, Mycoses,
P Campomenosi, and G Fronza, and L Ottaggio, and S Roncella, and A Inga, and M Bogliolo, and P Monti, and P Assereto, and F Moro, and G Cutrona, and S Bozzo, and N Chiorazzi, and A Abbondandolo, and M Ferrarini
September 2010, PloS one,
Copied contents to your clipboard!